Mainz Biomed (NASDAQ:MYNZ) versus CAE (NYSE:CAE) Head-To-Head Analysis

Mainz Biomed (NASDAQ:MYNZ) and CAE (NYSE:CAE) are both industrials companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Earnings & Valuation

This table compares Mainz Biomed and CAE”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	11.69	-$21.65 million	($65.60)	-0.01
CAE	$4.99 billion	1.65	$226.62 million	$0.65	39.60

CAE has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than CAE, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.4% of CAE shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 18.3% of CAE shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Mainz Biomed and CAE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
CAE	6.36%	7.45%	3.51%

Analyst Recommendations

This is a breakdown of recent ratings for Mainz Biomed and CAE, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
CAE	1	4	6	0	2.45

CAE has a consensus target price of $33.33, indicating a potential upside of 29.50%. Given CAE’s stronger consensus rating and higher possible upside, analysts clearly believe CAE is more favorable than Mainz Biomed.

Risk and Volatility

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, CAE has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.

Summary

CAE beats Mainz Biomed on 13 of the 14 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About CAE

CAE Inc., together with its subsidiaries, provides simulation training and critical operations support solutions in Canada, the United States, the United Kingdom, Europe, Asia, the Oceania, Africa, and Rest of the Americas. It operates through two segments, Civil Aviation; and Defense and Security. The Civil Aviation segment offers training solutions for flight, cabin, maintenance, and ground personnel in commercial, business, and helicopter aviation; a range of flight simulation training devices; and ab initio pilot training and crew sourcing services, as well as aircraft flight operations solutions. The Defense and Security segment operates as a training and simulation provider that delivers platform-independent solutions to enable and enhance force readiness and security for defense forces, original equipment manufacturers (OEMs), government agencies, and public safety organizations. The company was formerly known as CAE Industries Ltd. and changed its name to CAE Inc. in 1993. CAE Inc. was incorporated in 1947 and is headquartered in Saint-Laurent, Canada.